Nyaipriya Devi Sanglakpam,
- Student, Department of Biotechnology, Ramaiah University of Applied Sciences, Mathikere, Karnataka, India
Abstract
Objective: Phosphoinositide 3-kinases (PI3Ks), the target of rapamycin (PI3K/Akt/mTOR, PAM), are a family of enzymes that play a role in the growth, proliferation, differentiation, motility, survival, and intracellular trafficking of cells, all of which are essential for healthy cellular function and are also connected to cancer. In this study, quinoline and its derivatives were employed to analyze its inhibition activity on the phosphoinositide-3-kinase pathway. Methods: In this work, eight phytocompounds from quinoline were chosen, and the phosphoinositide-3-kinase pathway was analyzed to assess their multitarget mechanism. The study was carried out computationally utilizing PubChem as a data source and the molecular structures of the phytocompounds, as well as Indian medicinal plants, phytochemistry, and treatments. For the pharmacological evaluation of these drugs under the ADME properties for toxicity prediction, several additional approaches were applied. Results: The docking data revealed that eight analogs of quinoline were the most potent inhibitors for the proteins, Akt PBD 3MV5, PDK1 3RWQ, PIK3 3S2A, and mTOR-4DRI. Conclusion: All these bioactive compounds could be regarded as worthy candidates for the inhibition of the phosphoinositide-3-kinase pathway due to their high affinity for the protein.
Keywords: Phosphoinositide 3-kinase pathway, quinoline, 4DRI protein, 3MV5 protein, 3S2A protein, 3RWQ protein, multitarget mechanism
[This article belongs to International Journal of Molecular Biotechnological Research ]
Nyaipriya Devi Sanglakpam. In Silico Prediction of Multitarget Mechanism of Quinoline and Its Analogs on Phosphoinositide-3- Kinase Pathway Proteins. International Journal of Molecular Biotechnological Research. 2023; 01(01):57-76.
Nyaipriya Devi Sanglakpam. In Silico Prediction of Multitarget Mechanism of Quinoline and Its Analogs on Phosphoinositide-3- Kinase Pathway Proteins. International Journal of Molecular Biotechnological Research. 2023; 01(01):57-76. Available from: https://journals.stmjournals.com/ijmbr/article=2023/view=106800
References
1. Popova NV, Jücker M. The role of mTOR signaling as a therapeutic target in cancer. Int J Mol Sci. 2021;22(4):1743. doi: 10.3390/ijms22041743.
2. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464. doi: 10.3390/ijms22073464.
3. Singh P, Bast F. Multitargeted molecular docking study of plant-derived natural products on phosphoinositide-3 kinase pathway components. Med Chem Res. 2014;23(4):1690–700. doi: 10.1007/s00044–013–0774–2.
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–7. doi: 10.1126/science.296.5573.1655.
5. Ilakiyalakshmi M, Arumugam Napoleon AA. Review on recent development of quinoline for anticancer activities. Arab J Chem. 2022;15(11):104168. doi: 10.1016/j.arabjc.2022.104168.
6. Ma X, Shen L, Zhang J, Liu G, Zhan S, Ding B et al. Novel 4-acrylamido-quinoline derivatives as potent PI3K/mTOR dual inhibitors: the design, synthesis, and in vitro and in vivo biological evaluation. Front Chem. 2019;7:236. doi: 10.3389/fchem.2019.00236.
7. Moor LFE, Vasconcelos TRA, da R Reis R, Pinto LSS, da Costa TM. Quinoline: an attractive scaffold in drug design. Mini Rev Med Chem. 2021;21(16):2209–26. doi: 10.2174/1389557521666210210155908.
8. Jain S, Chandra V, Kumar Jain PK, Pathak K, Pathak D, Vaidya A. Comprehensive review on current developments of quinoline-based anticancer agents. Arab J Chem. 2019;12(8):4920–46. doi: 10.1016/j.arabjc.2016.10.009.
9. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry and Therapeutics. Sci Rep. 2018;8(1):4329. doi: 10.1038/s41598–018–22631-z.
10. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–95. doi: 10.1093/nar/gkaa971.
11. Burley SK, Berman HM, Kleywegt GJ, Markley JL, Nakamura H, Velankar S. Protein Data Bank (PDB): the single global macromolecular structure archive. Methods Mol Biol. 2017;1607:627–41. doi: 10.1007/978–1–4939–7000–1_26.
12. Kemmish H, Fasnacht M, Yan L. Fully automated antibody structure prediction using BIOVIA tools: validation study. PLOS ONE. 2017;12(5):e0177923. doi: 10.1371/journal.pone.0177923.
13. de Beer TA, Berka K, Thornton JM, Laskowski RA. PDBsum additions. Nucleic Acids Res. 2014;42((Database issue)):D292–6. doi: 10.1093/nar/gkt940.
14. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol. 2015;1263:243–50. doi: 10.1007/978–1–4939–2269–7_19.
15. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5-W14. doi: 10.1093/nar/gkab255.
16. Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22(1):173. doi: 10.3390/ijms22010173.
17. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–44. doi: 10.1038/nrd2926.
18. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. doi: 10.1186/s12943–019–0954-x.
| Volume | 01 |
| Issue | 01 |
| Received | 02/03/2023 |
| Accepted | 12/03/2023 |
| Published | 20/04/2023 |
| Publication Time | 49 Days |
Login
PlumX Metrics